In addition, reimbursement prices on certain managed treatment contracts that have been billed as out-of-network service provider position contributed to the lower previously. The Pharmacy Providers segment produced $15.4 million of segment Adjusted EBITDA, or 4.5 percent of segment revenue. This comes even close to $10.7 million, or 3.3 percent of segment revenue in the last year. Pharmacy Providers segment Adjusted EBITDA improved because of growth in discount money card program volumes, fresh managed care contracts, development in oncology, arthritis and multiple sclerosis therapies, and industry-wide drug inflation. Furthermore, the Pharmacy Solutions segment experienced a decrease in bad debt expense. Altogether, consolidated bad debt expenditure reduced from $5.3 million this year 2010 to $3.7 million in 2011.Related StoriesResearchers successfully repair nerve cell harm in Alzheimer's dementiaNew vaccine candidate shows great promise at fighting respiratory syncytial virusHIV, Ebola look like of animal origin’Our findings reveal a novel cellular control pathway that regulates the development of hepatitis C virus within the cell,’ said Dr. Stanley M. Lemon, director of the National Institutes of Health-funded Hepatitis C Analysis Center at UTMB and of the academic medical center’s Institute for Individual Attacks and Immunity.